MR-Linac Consortium
@mrlconsortium.bsky.social
Celebrating Global Collaboration in MR-Linac Research!
The MR-Linac Consortium continues to thrive as a truly international community, united by a shared mission to advance precision radiation therapy.
Don’t miss this conversation with Dr. Qian Peng, Radiation Oncologist in China: lnkd.in/eve3usMq
The MR-Linac Consortium continues to thrive as a truly international community, united by a shared mission to advance precision radiation therapy.
Don’t miss this conversation with Dr. Qian Peng, Radiation Oncologist in China: lnkd.in/eve3usMq
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
November 17, 2025 at 10:48 AM
Celebrating Global Collaboration in MR-Linac Research!
The MR-Linac Consortium continues to thrive as a truly international community, united by a shared mission to advance precision radiation therapy.
Don’t miss this conversation with Dr. Qian Peng, Radiation Oncologist in China: lnkd.in/eve3usMq
The MR-Linac Consortium continues to thrive as a truly international community, united by a shared mission to advance precision radiation therapy.
Don’t miss this conversation with Dr. Qian Peng, Radiation Oncologist in China: lnkd.in/eve3usMq
At the 20th Consortium meeting, it was inspiring to connect with so many members and see the progress being made in MRgRT. We're grateful to all who contributed their expertise and enthusiasm. Until next time!
November 12, 2025 at 10:46 AM
At the 20th Consortium meeting, it was inspiring to connect with so many members and see the progress being made in MRgRT. We're grateful to all who contributed their expertise and enthusiasm. Until next time!
We are thrilled that Rad Chat joined us at the MR-Linac Consortium meeting!
Rad Chat is a multi award winning podcast, education and social media platform focusing on radiotherapy and oncology. Curious to hear what Consortium attendees shared with them. Listen here: radchat.transistor.fm/episodes
Rad Chat is a multi award winning podcast, education and social media platform focusing on radiotherapy and oncology. Curious to hear what Consortium attendees shared with them. Listen here: radchat.transistor.fm/episodes
November 7, 2025 at 4:10 PM
We are thrilled that Rad Chat joined us at the MR-Linac Consortium meeting!
Rad Chat is a multi award winning podcast, education and social media platform focusing on radiotherapy and oncology. Curious to hear what Consortium attendees shared with them. Listen here: radchat.transistor.fm/episodes
Rad Chat is a multi award winning podcast, education and social media platform focusing on radiotherapy and oncology. Curious to hear what Consortium attendees shared with them. Listen here: radchat.transistor.fm/episodes
Today we awarded the best clinical, technical and young investigator abstracts. Congrats to this year's winners: Julia Peltenburg and Marlies Nowee, Xiangyu Zhang and Tariq Lalmahomed for their work in motion management, prostate cancer QoL and liver oligometastases treatment.
November 7, 2025 at 11:24 AM
Today we awarded the best clinical, technical and young investigator abstracts. Congrats to this year's winners: Julia Peltenburg and Marlies Nowee, Xiangyu Zhang and Tariq Lalmahomed for their work in motion management, prostate cancer QoL and liver oligometastases treatment.
The MR-Linac Consortium meeting kicked off today with 300+ members focused on sharing clinical data, research and the future of MRgRT. Huge thanks to our 2025 Organization Committee and Clinical Steering Committee Chair, Dr. Alison Tree, for driving MR-adaptive forward.
November 5, 2025 at 11:18 AM
The MR-Linac Consortium meeting kicked off today with 300+ members focused on sharing clinical data, research and the future of MRgRT. Huge thanks to our 2025 Organization Committee and Clinical Steering Committee Chair, Dr. Alison Tree, for driving MR-adaptive forward.
📄 This MOMENTUM study highlights the safety and tolerability of MRI-guided SBRT for liver metastases, showing promising results in maintaining disease control with manageable side effects. Patients reported a stable quality of life throughout treatment.
lnkd.in/eN8sEzmz
#MOMENTUM #LiverCancer
lnkd.in/eN8sEzmz
#MOMENTUM #LiverCancer
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 24, 2025 at 8:58 AM
📄 This MOMENTUM study highlights the safety and tolerability of MRI-guided SBRT for liver metastases, showing promising results in maintaining disease control with manageable side effects. Patients reported a stable quality of life throughout treatment.
lnkd.in/eN8sEzmz
#MOMENTUM #LiverCancer
lnkd.in/eN8sEzmz
#MOMENTUM #LiverCancer
Research from UTSW explores how PSMA-PET imaging can guide adaptive SABR in high-risk prostate cancer—refining tumor boosts based on response, without adding treatment time. MR-Linac and CBCT systems can offer practical paths to personalized, biology-driven radiotherapy.
lnkd.in/e4pHnZg2
lnkd.in/e4pHnZg2
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 8, 2025 at 1:23 PM
Research from UTSW explores how PSMA-PET imaging can guide adaptive SABR in high-risk prostate cancer—refining tumor boosts based on response, without adding treatment time. MR-Linac and CBCT systems can offer practical paths to personalized, biology-driven radiotherapy.
lnkd.in/e4pHnZg2
lnkd.in/e4pHnZg2
We’re thrilled to announce that the speaker lineup for the MR-Linac Consortium Meeting this November is confirmed!
Last year’s meeting brought together brilliant minds, bold ideas, and transformative conversations in MR-guided radiotherapy and this year promises to be even more impactful.
Last year’s meeting brought together brilliant minds, bold ideas, and transformative conversations in MR-guided radiotherapy and this year promises to be even more impactful.
October 3, 2025 at 9:29 AM
We’re thrilled to announce that the speaker lineup for the MR-Linac Consortium Meeting this November is confirmed!
Last year’s meeting brought together brilliant minds, bold ideas, and transformative conversations in MR-guided radiotherapy and this year promises to be even more impactful.
Last year’s meeting brought together brilliant minds, bold ideas, and transformative conversations in MR-guided radiotherapy and this year promises to be even more impactful.
This study explores the feasibility and early outcomes of MR-guided stereotactic ablative radiotherapy (MRgSTAR) for patients with synchronous oligometastatic prostate cancer (OMPC).
✅ 100% 3-year overall survival
✅ 95.2% progression-free survival
www.frontiersin.org/journals/onc...
✅ 100% 3-year overall survival
✅ 95.2% progression-free survival
www.frontiersin.org/journals/onc...
Frontiers | Stereotactic total ablative radiotherapy with MR-LINAC for synchronous oligometastatic prostate cancer
ObjectivesTo prospectively investigate the feasibility, toxicity, and preliminary clinical outcomes of magnetic resonance (MR)-guided stereotactic total abla...
www.frontiersin.org
September 22, 2025 at 12:53 PM
This study explores the feasibility and early outcomes of MR-guided stereotactic ablative radiotherapy (MRgSTAR) for patients with synchronous oligometastatic prostate cancer (OMPC).
✅ 100% 3-year overall survival
✅ 95.2% progression-free survival
www.frontiersin.org/journals/onc...
✅ 100% 3-year overall survival
✅ 95.2% progression-free survival
www.frontiersin.org/journals/onc...
This retrospective analysis of five patients treated in the MOMENTUM study highlights that daily MR-adaptation reduces dose variability and OAR exposure compared to MR-guided plans alone for cervical cancer.
#CervicalCancer #MOMENTUM
medicaljournalssweden.se/actaoncologi...
#CervicalCancer #MOMENTUM
medicaljournalssweden.se/actaoncologi...
Quantifying the dosimetric impact of online daily adaptation for MR-guided RT in cervical cancer
| Acta Oncologica
medicaljournalssweden.se
September 11, 2025 at 2:00 PM
This retrospective analysis of five patients treated in the MOMENTUM study highlights that daily MR-adaptation reduces dose variability and OAR exposure compared to MR-guided plans alone for cervical cancer.
#CervicalCancer #MOMENTUM
medicaljournalssweden.se/actaoncologi...
#CervicalCancer #MOMENTUM
medicaljournalssweden.se/actaoncologi...
August 19, 2025 at 1:49 PM
🚨A recent study leveraging MOMENTUM’s extensive dataset underlines that online adaptive MR-guided radiotherapy (MRgRT) shows promise for patients with non-metastatic pancreatic cancer.
✅ Maintained quality of life
✅ Significant symptom improvement at 6 months
www.redjournal.org/article/S036...
✅ Maintained quality of life
✅ Significant symptom improvement at 6 months
www.redjournal.org/article/S036...
Quality of Life and Toxicity in Patients With Pancreatic Ductal Adenocarcinoma Treated With Online Adaptive Stereotactic Magnetic Resonance Guided Radiation Therapy
Online adaptive magnetic resonance guided radiation therapy (MRgRT) using a hybrid
magnetic resonance imaging and linear accelerator enables stereotactic ablative radiation
doses to pancreatic tumors....
www.redjournal.org
August 14, 2025 at 1:56 PM
🚨A recent study leveraging MOMENTUM’s extensive dataset underlines that online adaptive MR-guided radiotherapy (MRgRT) shows promise for patients with non-metastatic pancreatic cancer.
✅ Maintained quality of life
✅ Significant symptom improvement at 6 months
www.redjournal.org/article/S036...
✅ Maintained quality of life
✅ Significant symptom improvement at 6 months
www.redjournal.org/article/S036...
Advancing MR-Guided Radiotherapy in Esophageal Cancer
A recent study from UMC Utrecht, explores the ATS-lite workflow—a simplified approach to online adaptive MRgRT which streamlines treatment delivery to a median of 23 minutes, while maintaining 90% target coverage.
A recent study from UMC Utrecht, explores the ATS-lite workflow—a simplified approach to online adaptive MRgRT which streamlines treatment delivery to a median of 23 minutes, while maintaining 90% target coverage.
A simplified online adaptive workflow for long-course magnetic resonance-guided radiotherapy in esophageal cancer
Since the publication of the landmark CROSS trial in 2012 [1], neoadjuvant chemoradiotherapy
has become a cornerstone in the curative treatment of esophageal cancer in much of
the western world. The r...
www.phiro.science
August 6, 2025 at 3:54 PM
Advancing MR-Guided Radiotherapy in Esophageal Cancer
A recent study from UMC Utrecht, explores the ATS-lite workflow—a simplified approach to online adaptive MRgRT which streamlines treatment delivery to a median of 23 minutes, while maintaining 90% target coverage.
A recent study from UMC Utrecht, explores the ATS-lite workflow—a simplified approach to online adaptive MRgRT which streamlines treatment delivery to a median of 23 minutes, while maintaining 90% target coverage.
Researchers in Nijmegen, Netherlands, have created an open-access online tool for early economic evaluation. This tool provides insights into the cost-effectiveness of MRIgRT. lnkd.in/e2sRxFRs
Users can input their own data lnkd.in/erDkxXpF
www.mrlconsortium.org
hashtag#ProgressThroughCollaboration
Users can input their own data lnkd.in/erDkxXpF
www.mrlconsortium.org
hashtag#ProgressThroughCollaboration
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
August 1, 2025 at 2:20 PM
Researchers in Nijmegen, Netherlands, have created an open-access online tool for early economic evaluation. This tool provides insights into the cost-effectiveness of MRIgRT. lnkd.in/e2sRxFRs
Users can input their own data lnkd.in/erDkxXpF
www.mrlconsortium.org
hashtag#ProgressThroughCollaboration
Users can input their own data lnkd.in/erDkxXpF
www.mrlconsortium.org
hashtag#ProgressThroughCollaboration
Reposted by MR-Linac Consortium
Excited to see the MARS trial highlighted here @cihangani.bsky.social @elekta.com @mrlconsortium.bsky.social @momentumstudy.bsky.social
June 27, 2025 at 11:12 AM
Excited to see the MARS trial highlighted here @cihangani.bsky.social @elekta.com @mrlconsortium.bsky.social @momentumstudy.bsky.social
🗓️Is it time to retire the PTV concept? In this article, members of the MR-Linac Consortium in the Netherlands discuss advancements in online adaptive radiation therapy (RT) and its implications for planning target volume margins. 📊
www.redjournal.org/article/S036...
www.redjournal.org/article/S036...
Toward the End of Planning Target Volume Margins With Online Adaptive Radiation Therapy
Radiation therapy aims to cure patients by delivering the prescribed dose to the tumor
with high precision. In the presence of positioning uncertainties, the question arises
how to ensure that the act...
www.redjournal.org
July 7, 2025 at 12:28 PM
🗓️Is it time to retire the PTV concept? In this article, members of the MR-Linac Consortium in the Netherlands discuss advancements in online adaptive radiation therapy (RT) and its implications for planning target volume margins. 📊
www.redjournal.org/article/S036...
www.redjournal.org/article/S036...
This study from Brescia compared Elekta Unity with Accuray Radixact outcomes for oropharyngeal cancer treatment. It shows that daily ATS workflow for treatment is feasible and well-tolerated, with potential advantages compared to helical tomotherapy.
www.ctro.science/article/S240...
www.ctro.science/article/S240...
Adaptive radiotherapy for oropharyngeal cancer with daily adapt-to-shape workflow on 1.5 T MRI-linac: Preliminary outcomes and comparison with helical tomotherapy
Oropharyngeal squamous cell carcinoma (OPSCC) is among the ten most common cancers
worldwide and its incidence is growing due to increased exposure to major risk factors,
including human papilloma vir...
www.ctro.science
June 23, 2025 at 10:21 AM
This study from Brescia compared Elekta Unity with Accuray Radixact outcomes for oropharyngeal cancer treatment. It shows that daily ATS workflow for treatment is feasible and well-tolerated, with potential advantages compared to helical tomotherapy.
www.ctro.science/article/S240...
www.ctro.science/article/S240...
🔬 Transforming Cancer Care
💡 Explore how we're shaping the future of cancer care through:
✔️ Cutting-edge clinical research
✔️ A community dedicated to advancing patient outcomes
✔️ A global network of experts and institutions
🌐 Learn more at www.mrlconsortium.org
#ProgressThroughCollaboration
💡 Explore how we're shaping the future of cancer care through:
✔️ Cutting-edge clinical research
✔️ A community dedicated to advancing patient outcomes
✔️ A global network of experts and institutions
🌐 Learn more at www.mrlconsortium.org
#ProgressThroughCollaboration
June 18, 2025 at 9:43 AM
🔬 Transforming Cancer Care
💡 Explore how we're shaping the future of cancer care through:
✔️ Cutting-edge clinical research
✔️ A community dedicated to advancing patient outcomes
✔️ A global network of experts and institutions
🌐 Learn more at www.mrlconsortium.org
#ProgressThroughCollaboration
💡 Explore how we're shaping the future of cancer care through:
✔️ Cutting-edge clinical research
✔️ A community dedicated to advancing patient outcomes
✔️ A global network of experts and institutions
🌐 Learn more at www.mrlconsortium.org
#ProgressThroughCollaboration
The HERMES trial from RMH London studied two MRI-guided adaptive prostate radiotherapy regimens. Both 5 and 2 fraction treatments are feasible with encouraging toxicity outcomes.
www.redjournal.org/article/S036...
@prostatecanceruk.bsky.social
www.redjournal.org/article/S036...
@prostatecanceruk.bsky.social
HERMES: Randomised trial of 2-fraction or 5-fraction MRI-guided adaptive prostate radiotherapy
To demonstrate safety and feasibility of 2-fraction stereotactic body radiotherapy
(SBRT) for prostate cancer.
www.redjournal.org
May 30, 2025 at 10:27 AM
The HERMES trial from RMH London studied two MRI-guided adaptive prostate radiotherapy regimens. Both 5 and 2 fraction treatments are feasible with encouraging toxicity outcomes.
www.redjournal.org/article/S036...
@prostatecanceruk.bsky.social
www.redjournal.org/article/S036...
@prostatecanceruk.bsky.social